148 related articles for article (PubMed ID: 16454729)
1. Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.
Boehrer S; Nowak D; Hoelzer D; Mitrou PS; Chow KU
Curr Pharm Des; 2006; 12(1):111-28. PubMed ID: 16454729
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Hayashi Y
Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
[TBL] [Abstract][Full Text] [Related]
3. Old, new drugs and new, new drugs for the new millennium.
Scheinberg DA
Curr Oncol Rep; 2000 Mar; 2(2):112-3. PubMed ID: 11122831
[No Abstract] [Full Text] [Related]
4. Targeted therapy and hematological malignancy.
Armitage JO
Target Oncol; 2009 Jan; 4(1):1-2. PubMed ID: 19343296
[No Abstract] [Full Text] [Related]
5. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
6. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for the treatment of leukemia.
Stull DM
Semin Oncol Nurs; 2003 May; 19(2):90-7. PubMed ID: 12830733
[TBL] [Abstract][Full Text] [Related]
8. Old disease, new targets. Part-II, haematological malignancies.
Kumar S; Masood N; Adil SN
J Pak Med Assoc; 2009 Aug; 59(8):555-61. PubMed ID: 19757705
[TBL] [Abstract][Full Text] [Related]
9. [Arsenic treatment for leukemia: new model of human cancer target treatment].
Zhao WW; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):439-40. PubMed ID: 15854545
[No Abstract] [Full Text] [Related]
10. [Resistance to target-based therapy and its circumvention].
Nishio K
Nihon Rinsho; 2004 Jul; 62(7):1343-7. PubMed ID: 15283154
[TBL] [Abstract][Full Text] [Related]
11. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
13. Novel therapies for multiple myeloma.
Ryoo JJ; Cole CE; Anderson KC
Blood Rev; 2002 Sep; 16(3):167-74. PubMed ID: 12163002
[TBL] [Abstract][Full Text] [Related]
14. [Tyrosine kinase inhibitors].
Yagasaki F
Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1411-9. PubMed ID: 17682429
[No Abstract] [Full Text] [Related]
15. Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center.
Büchler T; Hermosilla M; Ferra C; Encuentra M; Gallardo D; Berlanga J; Sarra J; Grañena A
Hematology; 2003 Jun; 8(3):145-50. PubMed ID: 12745647
[TBL] [Abstract][Full Text] [Related]
16. Cancer treatment. New drugs, new hope.
Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
[No Abstract] [Full Text] [Related]
17. The promise of gene expression analysis in hematopoetic malignancies.
Radich JP
Biochim Biophys Acta; 2002 Mar; 1602(1):88-95. PubMed ID: 11960697
[No Abstract] [Full Text] [Related]
18. Researchers optimistic about sea change in cancer treatment.
Stephenson J
JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
[No Abstract] [Full Text] [Related]
19. [Autophagy in hematologic malignancies].
Adachi S
Rinsho Ketsueki; 2009 Oct; 50(10):1531-8. PubMed ID: 19915363
[No Abstract] [Full Text] [Related]
20. [Molecular targeted therapy].
Stenner-Liewen F; Zippelius A; Pestalozzi BC; Knuth A
Chirurg; 2006 Dec; 77(12):1118-25. PubMed ID: 17109101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
